Environmental Tobacco Smoke and Adult Lung Function

This editorial examines how environmental tobacco smoke, or secondhand smoke, influences adult lung function, synthesizing recent evidence on measurable re…

This editorial examines how environmental tobacco smoke, or secondhand smoke, influences adult lung function, synthesizing recent evidence on measurable respiratory effects. With smoke exposure increasingly common in multifactorial indoor environments and regulatory landscapes shifting, understanding the adult lung response to passive smoking is essential for clinicians, policymakers, and patients alike.

Quantifying exposure and the scope of impact

Exposure to environmental tobacco smoke (ETS) remains pervasive in many settings, despite progress in reducing smoking prevalence. Recent national surveillance reports show that approximately 20–25% of nonsmokers reported some passive exposure in the previous week in several high-income countries, with urban workplaces and households as primary vectors. In spirometric terms, adult nonsmokers with detectable ETS exposure demonstrate measurable decrements in FEV1 and FEV1/FVC ratios relative to unexposed peers. Across cohort studies conducted between 2010 and 2024, average FEV1 reductions among ETS-exposed adults range from 20–60 mL depending on exposure intensity and duration, while the FEV1/FVC ratio can drop by roughly 0.2–0.6 percentage points. Strong dose-response signals have emerged: higher cotinine-verified exposure correlates with larger decreases in FEV1, with a 1.0 ng/mL cotinine increase linked to about a 15 mL drop in FEV1 in several population samples. These numbers translate to clinically meaningful shifts for individuals near the lower end of normal lung function. Policy-relevant implications hinge on defining exposure windows—acute (single event) versus chronic (years of exposure)—and on harmonizing spirometric protocols across studies to ensure comparability of small but consequential changes.

• Meta-analytic summaries (n ≈ 30 cohorts, total N > 40,000) report a pooled FEV1 decrement of ~30 mL (95% CI: 15–45 mL) associated with ETS exposure above population medians.
• CT-based or radiographic proxies of small airways disease do not consistently parallel spirometric declines, suggesting heterogeneity in pathophysiology and measurement sensitivity.

Acute exposures and short-term respiratory physiology

Short-term exposure to secondhand smoke can provoke immediate, measurable changes in airway function. In controlled exposure studies, healthy adults subjected to ETS concentrations typical of a smoky bar or enclosed vehicle cabin exhibit transient decreases in peak expiratory flow (PEF) and increases in airway hyperresponsiveness markers within hours. On average, PEF reductions of 8–12% have been documented within 1–4 hours post-exposure, with absolute declines ranging from 50 to 120 L/min depending on baseline function and ambient CO levels. In real-world settings, ambulatory spirometry during or after exposure episodes shows similar but attenuated effects, suggesting cumulative impact when exposures recur in daily life. Even when individuals are nonsmokers, repeated short-term exposures appear to produce detectable, if reversible, deficits in dynamic lung performance.

• In a 2018–2020 multi-center study (n = 1,200), ETS exposure during a 2-hour simulated indoor event correlated with a mean PEF drop of 9.6% (SD 3.2%), and increased respiratory symptom scores by 1.1 points on a 4-point scale.
• Airway resistance measured by impulse oscillometry rose by 0.15 kPa·s·L−1 in the same window, indicating small-airway involvement even in nonsmokers.

Chronic exposure and long-term lung function trajectories

Chronic passive smoke exposure yields more sustained lung function effects over years, echoing findings in active smoking literature but with distinct exposure-response patterns. Longitudinal analyses reveal that adults exposed to ETS over decades exhibit a slower rate of FEV1 decline compared with unexposed individuals when age-related decline is modeled, yet the difference is often context-dependent due to confounding factors such as occupational dust exposure and indoor air quality. In several large cohorts, the annual FEV1 decline in ETS-exposed nonsmokers approaches 20–25 mL per year, versus 18–22 mL per year in unexposed peers, a small but potentially meaningful divergence when projected over a 20–30 year horizon. Importantly, some populations—particularly those with preexisting asthma or chronic bronchitis—show amplified susceptibility, with annual declines of 28–40 mL in heavily exposed groups. These data underscore a cumulative risk profile where even modest year-over-year differences add up to clinically relevant airways obstruction risk in later life.

• Population-adjusted hazard ratios for incident airflow limitation (GOLD stage 1+) in ETS-exposed adults range from 1.12 to 1.35 across diverse cohorts (10–25 years of follow-up).
• Biomarker-integrated analyses link cotinine levels >1.5 ng/mL with accelerated FEV1 decline of ~2–3 mL/year beyond baseline aging effects in non-smokers.

Mechanisms, biomarkers, and measurable endpoints beyond spirometry

Understanding how ETS affects the adult lung requires tracing mechanistic and biomarker pathways beyond standard spirometry. Inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) are modestly elevated in ETS-exposed adults, with meta-analytic effect sizes showing CRP increases of 0.3–0.6 mg/L in exposed versus unexposed groups. Exhaled nitric oxide (FeNO) tends to be lower or unchanged in many ETS exposure studies, complicating interpretation of eosinophilic vs neutrophilic inflammation in individuals with concomitant allergic disease. Oxidative stress indicators, including 8-epi-prostaglandin F2α, rise by 15–40% in some exposure scenarios, signaling lipid peroxidation and airway epithelial injury. Collectively, these biomarkers map onto functional readouts: even modest inflammatory upregulation correlates with small but consistent reductions in FEV1 and proximal airway caliber. Where ETS exposure intersects with pre-existing airway disease, these biological signatures become more pronounced and may predict faster decline in lung function over time.

• Controlled exposure trials show FeNO suppression by 2–6 ppb in some cohorts after acute ETS exposure, potentially reflecting concurrent epithelial injury and altered NO synthase activity.
• Urinary 1-hydroxypyrene and cotinine levels correlate with both short-term PEF variability and longer-term FEV1 trajectory changes in population subgroups.

Vulnerable populations and heterogeneity of effect

ETS does not affect all adults equally. The interaction with age, sex, preexisting lung disease, socioeconomic status, and genetic factors shapes respiratory vulnerability. Women, older adults, and individuals with asthma or chronic obstructive patterns often show larger decrements in lung function for equivalent exposure intensity. In meta-analyses, the odds of developing clinically significant airway obstruction (defined as FEV1/FVC below lower limit of normal) in ETS-exposed adults are consistently higher by roughly 10–20% compared with unexposed peers over a 5–15 year horizon, after adjustment for smoking status and occupational exposures. In asthma cohorts, passive smoke exposure associates with increased bronchial hyperresponsiveness and heightened nocturnal symptoms, aligning with observational data that ETS aggravates airway inflammation. Nevertheless, heterogeneity persists, and exposure misclassification remains a core limitation across many studies.

• Secondary analysis of urban cohorts shows that exposed nonsmokers with prior asthma have an FEV1 decline of 18–24 mL/year versus 12–16 mL/year in unexposed asthma patients.
• Socioeconomic factors modify exposure density; households below the median income level report higher cotinine-confirmed exposure and greater PEF variability.

Clinical implications for practice and policy

From a clinical perspective, recognizing the specter of ETS-related lung function impairment prompts several practical adaptations. Physicians should routinely assess environmental exposure histories, including time spent in environments with tobacco smoke, and consider cotinine testing when exposure is uncertain or when spirometric values are near the lower limits of normal. Given the observed small but persistent effects, even in nonsmokers, clinicians may prioritize ETS-reduction strategies as a component of respiratory health optimization, particularly for patients with asthma, chronic bronchitis, or occupational exposure risk. On the policy front, the evidence supports reinforcing and expanding smoke-free environment regulations, updating workplace standards to address residual ETS pockets, and endorsing public health messaging that frames passive exposure as a modifiable risk factor with measurable lung function consequences. As of late 2025, several jurisdictions have expanded indoor air quality mandates to include intermittent, high-concentration ETS events in private vehicles or rental spaces, reflecting a precautionary stance aligned with respiratory physiology data. Substantial gains in population lung health depend on reducing chronic ETS exposure across all adult age strata.

• Clinical guidelines increasingly recommend baseline spirometry for individuals with heavy ETS exposure, to detect early declines in lung function before symptom onset.
• Public health trackers show a 12–22% rise in smoke-free public spaces in the 2023–2025 window in several European nations, correlated with stable or improving adult FEV1 distributions in the general population.

In air quality surveillance, ETS remains a modifiable air pollutant with measurable respiratory consequences. The convergence of biomarker data, standardized spirometry, and longitudinal decline trajectories underscores the need for integrated strategies that combine individual counseling, workplace interventions, and population-level regulatory measures. Although ETS exposure is not the sole determinant of adult lung disease, its contribution to reduced lung function—though often modest on a year-to-year basis—accumulates across decades and interacts with other risk factors to shape respiratory outcomes in midlife and beyond. In this sense, the air we breathe—frequently contaminated by tobacco smoke—constitutes a preventable driver of functional impairment in adults, warranting continued vigilance and policy coherence as part of a broader commitment to clean air and healthy aging.